Skip to main content
Submitted by on Thu, 11/19/2020 - 10:28

Egnyte Creates Platform to Accelerate the Discovery and Development of Life Sciences Innovation

Launches unified solution enabling companies to comply with GxP, adhere to data privacy laws, and facilitate collaboration; announces Advisory Board to shape new offerings and go-to-market strategies

Mountain View, CA. – November 19, 2020

Egnyte, the leader in cloud content governance, announced Egnyte for Life Sciences, a purpose-built platform to serve those advancing the science of health. Egnyte’s unified solution helps biotech, medical device, and diagnostics companies accomplish three outcomes quickly: meet regulatory compliance standards, expedite data sharing and collaboration, and secure essential intellectual property.

Life Sciences companies need to manage numerous content-rich workflows that are unique in both their complexity and compliance demands: clinical studies, quality documentation, and regulatory submissions, to name a few. With Egnyte for Life Sciences, these companies can now do so in a single piece of software. The platform provides robust document management capabilities to facilitate intra- and inter-institutional collaboration while maintaining compliance with FDA 21 CFR Part 11 directives.

At Fulcrum Therapeutics, a Cambridge, MA-based firm, Chris Moxham, a Ph.D. and SVP of Discovery Research, leverages Egnyte as a unified solution to enable collaboration, security, and compliance with regulatory frameworks. “There has been an explosion of data types, and the data sets we work with are quite large, things like high-content imaging and sequence data,” said Moxham, whose pioneering research centers on developing medicines that treat the root cause of genetically defined diseases. “The ability for Egnyte to store the data files on a compliant platform and provide seamless access to scientists so we can create knowledge and move forward has been invaluable.”

In addition to addressing the complexities of managing regulated data at different stages of drug development - from research to clinical trials to IPO - Egnyte for Life Sciences also helps companies with global reach address the complexity of operating under multiple privacy and compliance regimes. Leveraging machine learning, the platform will identify risks to sensitive data and automates compliance with, for example, data privacy laws, like GDPR and CCPA. The software provides real-time alerts for misclassified personally identifiable information and a single dashboard to remediate issues.

The launch is a continuation of Egnyte’s strategy of providing simple yet sophisticated cloud content governance, security, and compliance solutions to content-critical businesses.

Egnyte is also announcing the formation of a Life Sciences Advisory Board to shape its offerings and go-to-market strategy in the industry. Advisory Board members include a Nobel Laureate, prominent biotech venture capitalists, and experts in life sciences data management.

ABOUT EGNYTE

Egnyte provides the only unified cloud content governance solution for collaboration, data security, compliance, and threat prevention for multicloud businesses. More than 16,000 organizations trust Egnyte to reduce risks and IT complexity, prevent ransomware and IP theft, and boost employee productivity on any app, any cloud, anywhere. Investors include GV (formerly Google Ventures), Kleiner Perkins, Caufield & Byers and Goldman Sachs. For more information, visit  www.egnyte.com.


Global Press & Media Contact